04 December 2025

The invisible engine

When Joaquim Teixeira first heard about the Champalimaud Foundation (CF), it wasn’t in the media or a job ad, it was through a friend, who then invited him for a Happy Hour. “There were maybe twenty people at most, but the atmosphere had gravity. You could sense that something meaningful was about to happen and you wanted to be part of it”, he recalls.

04 December 2025

A story about curiosity, ingenuity and reinvention

The story of Cátia Feliciano and the Champalimaud Foundation (CF) began when she was still finishing her PhD in Neurobiology at Duke University in Durham, in the United States (USA). With a broad smile, she states that her great passion has always been neuroscience, and that when she heard of the plans to build a large research centre in Lisbon dedicated to this field, returning to Portugal became a possibility.

02 December 2025

Humanity of and in the future

João Santinha graduated in Biomedical Engineering from the Universidade Nova de Lisboa during one of the longest economic crises Portugal has ever experienced and it was during this time that he heard about the Champalimaud Foundation (CF) for the first time. In a period when there were few opportunities in his field of study, a position opened up on the Scientific Software team that interested him. “I wasn’t selected,” he says smiling, but he adds proudly, “I was invited to another position a few years later.”

28 November 2025

Pfizer Awards 2025 recognise two researchers from the Champalimaud Foundation

Personalised Medicine for Colorectal Cancer

In the Clinical Research category, the award went to Rita Fior, leader of the Cancer Development and Innate Immune Evasion Group, for the study “The zAvatar test forecasts clinical treatment response in patients with colorectal cancer: a co-clinical study paving the way for personalised medicine.” Bruna Costa, a postdoctoral researcher, is the first author of the recognised work.

Rui Costa

Fighting for the Future

On March 13, 2026, the Champalimaud Foundation will host the Lung Cancer Fight Club – 3rd Round, a multidisciplinary meeting bringing together renowned scientists and clinicians to discuss cutting-edge strategies in lung cancer management.

This year’s symposium will provide a platform for knowledge exchange across surgery, radiotherapy, interventional pulmonology, genetics, nutrition, physical activity, mental health, and applied technologies in oncology.

 

Programme

 

25 November 2025

Local roots, global reach

Before there was a building by the river, before there were retreats and bustling labs, there was only an idea and a handful of conversations sparked across Lisbon, Boston, and New York.

25 November 2025

From school to global impact: an international journey

When Tiago Santos first walked through the glass corridors of the Champalimaud Foundation (CF) in 2014, he already had two years of nursing experience, but none in urology or oncology. “Deep down, one could say I started a new chapter of my career here,” he admits with a wry smile. Indeed, stepping into a nearly empty unit with no reference guides, protocols, or precedents might have made most people run for the hills. But not Tiago. For him, the emptiness was an invitation: a white canvas on which to paint the future of urology nursing at CF.

24 November 2025

Your gut’s railway switch: how the “second brain” decides between attack and repair

The work fits into a broader effort to understand how the immune system maintains balance – a theme underscored by this year’s Nobel Prize in Physiology or Medicine for discoveries in immune tolerance.

21 Nov. 2025

MRI Technician (Preclinical MRI Platform)

Research
Application Starts: 21 Nov. 2025
Application Ends: 19 Dec. 2025


Offer Description

Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for a MRI Technician to join our team at the Champalimaud Research Program. 

Subscribe to Cancer
Loading
Please wait...